PTC Therapeutics (PTCT) 8-K Other Events

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 16, 2014

PTC THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-35969	04-3416587
(State or Other Jurisdiction of Incorporation	(Commission File Number)	(IRS Employer Identification No.)

100 Corporate Court South Plainfield, NJ	07080
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (908) 222-7000

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.  Other Events.

The previously announced underwritten public offering of 3,450,000 shares of common stock of PTC Therapeutics, Inc. (the “Company”), including 450,000 shares issued upon exercise by the underwriters of their option to purchase additional shares, closed on October 16, 2014.  The Company expects its net proceeds from this offering to be approximately $117.5 million, after deducting the underwriting discounts and commissions and estimated expenses payable by the Company.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PTC THERAPEUTICS, INC.
Date: October 16, 2014	By:	/s/ Shane Kovacs
		Shane Kovacs
		Chief Financial Officer

3